Skip to main content

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

An official website of the United States government
Grant Details

Grant Number: 5R01CA249506-04 Interpret this number
Primary Investigator: Braithwaite, Dejana
Organization: University Of Florida
Project Title: Personalized Screening for Lung Cancer: the Importance of CO-Existing Chronic Conditions to Clinical Practice and Policy
Fiscal Year: 2024


Abstract

Abstract / summary Lung cancer is the leading cause of cancer death in the US and worldwide, largely because most patients have advanced, incurable disease at the time of diagnosis. However, lung cancer screening (LCS) with low-dose computed tomography (LDCT) has the potential to revolutionize lung cancer outcomes through early detection. As LCS is disseminated into real-world settings and populations, a key outstanding question is whether the benefits/harms ratio found in clinical trials will apply to an older and sicker population. The basic conundrum facing LCS candidates is that the single risk factor most strongly linked to lung cancer -- smoking history -- is also strongly linked to morbidity and death from non-lung cancer causes (e.g. chronic obstructive pulmonary disease emphysema), which limit life expectancy and increase risk of complications from diagnostic or therapeutic procedures. The overarching goal of our proposed study is to precisely characterize this vulnerable subpopulation with high comorbidity burden, quantifying for them the benefits and harms of LCS to enable more informed decision-making by patients contemplating LCS. Our study will help close this knowledge gap by leveraging real-world data to more fully characterize this subpopulation of “marginal” LCS candidates, reducing the uncertainty currently facing patients and providers. More specifically, we propose to leverage electronic health records and claims data for patients ages 55-80 (n~34,039) undergoing annual screening with LDCT in geographically diverse real-world settings from 2016-2022. We will then use these observational data with validated models in the Cancer Intervention Simulation Network to simulate LCS outcomes in the real-world US population. By generating previously unavailable real-world data for use in validated simulation models, this proposal responds directly to calls to improve patient- centered decision-making in LCS candidates for whom the net benefits of screening are currently highly uncertain.



Publications

Error Notice

The database may currently be offline for maintenance and should be operational soon. If not, we have been notified of this error and will be reviewing it shortly.

We apologize for the inconvenience.
- The DCCPS Team.

Back to Top